Literature DB >> 20735333

Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.

Giuseppe Valenza1, Kerstin Radike, Christoph Schoen, Stephan Horn, Anett Oesterlein, Matthias Frosch, Marianne Abele-Horn, Helge Hebestreit.   

Abstract

Tobramycin and colistin represent 2 standard antimicrobial agents in the treatment of cystic fibrosis (CF) patients who are chronically colonized with Pseudomonas aeruginosa. In this study, we determined the rate of resistance to tobramycin and colistin in 1844 isolates of P. aeruginosa obtained from 22 CF patients under alternate therapy with inhaled tobramycin and colistin. Resistance to tobramycin was observed in 27.5% of isolates. In contrast, all isolates were susceptible to colistin. Molecular typing of selected isolates suggested that only 1 clone occurred over time in each patient. To conclude, resistance to tobramycin in P. aeruginosa isolates from CF patients under antimicrobial therapy may occur while colistin resistance remains uncommon.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20735333     DOI: 10.3109/00365548.2010.509333

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  4 in total

1.  Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.

Authors:  Muhammad-Hariri Mustafa; Hussein Chalhoub; Olivier Denis; Ariane Deplano; Anne Vergison; Hector Rodriguez-Villalobos; Michael M Tunney; J Stuart Elborn; Barbara C Kahl; Hamidou Traore; Francis Vanderbist; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

Review 2.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

Review 3.  Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy.

Authors:  Cordula Koerner-Rettberg; Manfred Ballmann
Journal:  Core Evid       Date:  2014-09-19

4.  Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.

Authors:  Gerard McCaughey; Paul Diamond; J Stuart Elborn; Matt McKevitt; Michael M Tunney
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.